EyeKor, Inc., an imaging and data management company for the ophthalmic pharmaceutical clinical trial and ocular preclinical laboratory industries, has announced that it is opening a new office in China to enhance its capability to provide local support for clinical trial sponsors and sites in China and the APAC region.
“Over the past few years, EyeKor has actively collaborated with partners in China, building successful relationships with sponsors, hospitals, academia, reading centres and trial sites. With this new office, EyeKor aims to build upon these partnerships as an imaging contract research organisation (CRO), providing focused support for ophthalmic clinical trials and vision science endeavours in China and the APAC region,” said an EyeKor spokesperson.
“EyeKor is proud to contribute to this momentous trend in China’s drug development paradigms. Establishing a team of imaging trial professionals who are well versed on international regulatory standards, EyeKor is positioned to assist sponsors in China in developing new and urgently needed therapies, particularly for patients suffering from ophthalmic diseases that currently lack approved effective treatments,” said the spokesperson.
EyeKor is dedicated to delivering excellence in data management and analysis services for clinical and preclinical studies and strives to provide added value to clinical trial projects through superior quality, services and deep scientific expertise.
EXCELSIOR is a unique data/imaging management platform offering from EyeKor and is an FDA 510(k)-cleared Class II medical device and compliant with HIPAA, 21 CFR Part 11 and other regulatory requirements.